Dopamine: The forgotten felon in type 2 diabetes

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 1, 2011, Pages 61-65

  Kalra, Sanjay ^a   Kalra, Bharti ^a   Agrawal, Navneet ^b   Kumar, Satish ^c  

^a Bharti Hospital ^*  (India)

^b University   (India)

^c Excel Life Sciences   (India)

Author keywords

Bromocriptine; Dopamine; Dopaminergic agents; Obesity; Type 2 diabetes

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; BROMOCRIPTINE; CABERGOLINE; CYCLOSPORIN; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE; HALOPERIDOL; HEMOGLOBIN A1C; INSULIN; MACROLIDE; METFORMIN; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; PHENYTOIN; PLACEBO; PROBENECID; RISPERIDONE; SALICYLIC ACID; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; SULPIRIDE;

ACROMEGALY; ARTICLE; CARDIOMYOPATHY; COMBINATION CHEMOTHERAPY; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENERGY; FOOD INTAKE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GYNECOLOGIC DISEASE; HALLUCINATION; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; INSULIN RESPONSE; LOW CALORY DIET; METABOLIC SYNDROME X; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTINOMA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; VENTRAL TEGMENTUM; VOMITING; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; BROMOCRIPTINE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; DRUG INTERACTIONS; ENERGY METABOLISM; GLUCOSE; HUMANS; PATENTS AS TOPIC;

EID: 79551642409     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411794351842     Document Type: Article

References (42)

1. De Fronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773-95.
2. Zhang CX, Tse LA, Ye XQ, Lin FY, Chen YM, Chen WQ. Moderating effects of coping styles on anxiety and depressive symptoms caused by psychological stress in Chinese patients with type 2 diabetes. Diabetic Med 2009; 26(12): 1282-8.
3. Caron MG, Gainetdinov RR. In: Dopamine Handbook. Oxford Scholarship Online Manographs 2009; 88-100.
4. Zimmermann M. Burgerstein's Handbook of Nutition. Stuttgart: Theime 2001; 107-8.
5. Garcia-Tornado I, Ornstein AM, Chamson-Reig A, Wheeler MB, Hill DJ, Rubinstein PM, et al. Disruption of TEJ dopamine D2 receptor impairs insulin secretion and glucose intolerance. Endocrinology 2010; 151 (4): 1441-50.
6. Cincotta AH, Tozzo E, Scislowski PWD. Bromocriptine/ SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997; 61(10): 951-6.
7. Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993; 264: E285-93.
8. Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 1991; 40: 639-44.
9. Cincotta AH, Meier AH, Southern LL. Bromocriptine alters hormone rhythms and lipid metabolism in swine. Ann Nutr Metab 1989; 33: 305-14.
10. Southern LL, Cincotta AH, Meier AH, Bidner TD, Watkins KL. Bromocriptine-induced reduction of body fat in pigs. J Anim Sci 1990; 68: 931-6.
11. Cincotta AH, Meier AH. Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Life Sci 1989; 45: 2247-54.
12. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61: 1356-70.
13. Sowell MO, Mukhopadhyaya N, Cavazzoni P, Shankar S, Steinberg HO, Brier A, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Cin Endocrinol Metab 2002; 87: 2918-23.
14. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004; 55: 1006-13.
15. Weil C. The safety of bromocriptine in long term use: a review of the literature. Curr Med Res Opin 1986; 10: 25-51.
16. Höfgen, N., Stange, H., Langen, B., Egerland, U., Schindler, R., Gasparic, A., Rundfeldt, C., Pfeifer, T. Methods of treating obesity and metabolic disorders. WO2009068246 (2009).
17. Gadde, K.M., Krishnan, K. R.R. Method for treating obesity. US7754748 (2010).
18. Cincotta, A.H., Meier, A.H. Therapeutic process for the treatment of the pathologies of type II diabetes. US5866584 (1999).
19. Cincotta, A.H., Cincotta, M., Pelloni, C.L., Runice, C.E., Tigner, S.L. Accelerated release composition containing bromocriptine. US5679685 (1997) & EP1258245A3 (2003).
20. Moro, L., Fiori, A., Natali, A. Processes for the preparation of pharmaceutical compositions containing bromocriptine having high stability and related products. US5066495 (1991) & EP0391374 (1994).
21. Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol 2001; 24: 247-53.
22. Jahnichen S, Horowski R, Pertz HH. Agonism of 5-HT2B is not a class effect of the ergolines. Eur J Pharmacol 2005; 513: 225-8.
23. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 1992; 48(3): 248-53.
24. Luo S, Luo J, Cincotta AH. Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int 2000; 17(2): 155-72.
25. Atkinson PR, Mahon JL, Dupre J, Stiller CR, Jenner MR, Paul TL, et al. Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: Results from the Canadian open study. J Autoimmun 1990; 3 (6): 793-9.
26. Feek CM, Bevan JS, Taylor S, Brown NS, Baird JD. The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly. Clin Endocrinol 1981; 15(5): 473-8.
27. Barnett AH, Chapman C, Gailer K, Hayter CJ. Effect of bromocriptine on maturity onset diabetes. Postgrad Med J 1980, 56: 11-4.
28. Lamberts SWJ, Klijn JGM, de Quijada M, Timmermans HAT, Uitterlinden P, de Jong FH, et al. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab 1980; 51(2): 307-11.
29. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19 (6): 667-70.
30. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004; 62: 55-9.
31. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: A novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-61.
32. Wasada T, Kawahara R, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000; 23: 1039-40.
33. Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33 (7): 1503-8.
34. Kalra B, Kalra S, Kumar A. GLP - 1 Analogs: Newer molecules, newer uses. Recent Pat Endocr Metab Immune Drug Discov 2009; 3: 129-34.
35. Via MA, Chandra H, Araki T, Potenza MV, Skamgas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes 2010; 3: 43-8.
36. Scobie IN, Kesson CM, Ratcliffe JG, Maccuish AC. The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus. Clin Endocrinol 1983; 18(2): 179-85.
37. Scranton R, Cincotta A. Bromocriptine -unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010; 11(2): 269-79.
38. Quick, M., Di Monte, D., Langston, J.W. Methods and compositions for reduction of side effects of therapeutic treatments. US7718677 (2010).
39. Kase, H., Mori, A., Waki, Y., Ohsawa, Y., Karasawa, A., Kuwana, Y. Administering adenosine A2A receptor antagonist to reduce or suppress side effects of Parkinson's disease therapy. US7727993 (2010).
40. Kerr JL, Timpe EM,Petcewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes management. Ann Pharmacother 2010; 44 (11): 1777-85
41. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-78.
42. Clausius N, Born C, Grunze H. The relevance of dopamine agonists in the treatment of depression. Neuropsychiatr 2009; 23: 15-25.